Fig. 1

High-throughput combinatorial drug screen. A The 320 compounds (probes) in the drug screen consist of clinically active or preclinical agents that target 22 broad biological pathways shown. B Schematic of the drug screen showing growth optimization of A375R1 and UCSD354L cells, followed by testing of five combinations of tenfold concentrations of anchor (IACS) and each of the 320 probes on these cells, counting cells after 72 h, and lastly an analytical pipeline to generate combo scores. C Combo scores shown as bar graphs, with a horizontal dashed line representing cutoff scores for synergy (> 0.1). D & E Probes that exhibited the highest synergistic inhibition of A375R1 and UCSD354L cells respectively in combination with IACS